Clinical Trials Logo

Pulmonary Neoplasms clinical trials

View clinical trials related to Pulmonary Neoplasms.

Filter by:

NCT ID: NCT05857995 Not yet recruiting - Lung Cancer Clinical Trials

Precision Lung Cancer Survivorship Care Intervention

KYLEADSII
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.

NCT ID: NCT05011890 Completed - Lung Cancer Clinical Trials

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®

LC-PRO
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate how Moovcare®, a mobile medical application, can be used to monitor Patient-Reported Outcomes (PROs) related to cancer treatment, cancer complications, and cancer relapse in patients with lung cancer. PROs are symptoms directly reported by patients through the completion of a survey. Up to 50 patients undergoing treatment and/or surveillance for new or existing diagnoses of lung cancer at the University of North Carolina's Lineberger Comprehensive Cancer Center will be prospectively enrolled to the use of the mobile medical application Moovcare® for 6 months. Moovcare® is not FDA approved, and its role in improving clinical care is being studied through this research. Moovcare® automatically delivers electronic patient reported outcome (ePRO) surveys on common symptoms experienced by lung cancer patients.

NCT ID: NCT04699188 Recruiting - Lung Cancer Clinical Trials

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KontRASt-01
Start date: February 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

NCT ID: NCT02673021 Terminated - Lung Cancer Clinical Trials

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

MARK 1A
Start date: June 8, 2016
Phase: N/A
Study type: Interventional

Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?

NCT ID: NCT02549638 Recruiting - Lung Cancer Clinical Trials

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

Start date: August 2015
Phase:
Study type: Observational

The study will utilize both retrospective and prospective data collection from patients that already had a bronchoscopy and lung resection or will have a bronchoscopy and lung resection for squamous cell carcinoma. The investigators plan to prospectively collect 5 bronchoscopic biopsies, 10ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria.

NCT ID: NCT02483052 Completed - Lung Neoplasms Clinical Trials

RejuvenAir Lobectomy for Safety and Histology

LobectomyCAN
Start date: August 2015
Phase: Phase 1/Phase 2
Study type: Interventional

RejuvenAir System treatment will be performed during preoperative bronchoscopy 2 to 90 days prior to prescheduled lung resection in Subjects requiring lobectomy for removal of peripheral tumors. Treatment will be limited to areas of the bronchi within the lobe that will be removed, distal to the anticipated margin of resection. Treatment should be at least 1 cm from the bronchial resection margins and away from the tumor bed. Treated airways will be inspected via bronchoscopy at the time of thoracotomy, and examined histologically following surgical resection. Subject participation will be from 1 to 90 days and enrollment is anticipated to take 3 months. Subject having a RejuvenAir procedure and not going on to a resection for any reason will be followed for a maximum of 90 days for safety and undergo bronchoscopic evaluation of the treated airways at 90 days (+/- 4 Days)) post treatment.

NCT ID: NCT02410603 Completed - Lung Cancer Clinical Trials

Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer

Start date: December 2016
Phase:
Study type: Observational

The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).

NCT ID: NCT02370303 Completed - Lung Cancer Clinical Trials

A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System

Start date: August 2014
Phase:
Study type: Observational

The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.

NCT ID: NCT01860898 Completed - Lung Cancer Clinical Trials

A Phase I Study of iPS Cell Generation From Patients With COPD

Start date: September 2009
Phase: N/A
Study type: Interventional

As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, the investigators will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells.

NCT ID: NCT01470248 Completed - Lung Cancer Clinical Trials

Study of Arsenic Trioxide in Small Cell Lung Cancer

Start date: August 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study the effect of an anticancer drug, Arsenic Trioxide, in patients with small cell lung cancer who have failed at least one standard chemotherapy regimen as well as patients who are unable to tolerate the standard treatment for their cancer. The investigators seek to establish the safety of and efficacy of Arsenic Trioxide in this patient group. The study will include up to 36 participants with small cell lung cancer. The investigators want to find out what effects, good or bad, that the study drug has on your cancer. This study will also look at specific biomarkers in your blood and in the tumor tissue which may help the investigators to determine if the levels of these biomarkers are related to tumor response to treatment. Arsenic Trioxide, also known by the brand name, Trisenox, is a chemotherapy drug approved by the Food and Drug Administration (FDA) for the treatment of a specific type of blood cancer called Acute Promyelocytic Leukemia. It works in part by making cancer cells become more mature thereby stopping them from growing in number and more likely to die off.